Custom Oligonucleotide Synthesis and Gene Synthesis Market Comprehensive Report: 200+ Pages | 2026–2034

Custom Oligonucleotide Synthesis and Gene Synthesis by Application (Commercial, Academic Research), by Types (Oligonucleotide Synthesis, Gene Synthesis), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Custom Oligonucleotide Synthesis and Gene Synthesis Market Overview

The Custom Oligonucleotide Synthesis and Gene Synthesis market encompasses the design, production, and supply of tailor‑made nucleic acid sequences for therapeutic, diagnostic, and research applications. Growing demand for personalized medicine, mRNA vaccines, and CRISPR‑based gene editing underscores its strategic relevance. According to recent industry estimates, the market size reached approximately $4.8 billion in 2025, and the Custom Oligonucleotide Synthesis and Gene Synthesis market size is projected to expand at a compound annual growth rate (CAGR) of about 9 % from 2026 to 2033, reflecting robust growth outlook, market forecast, and industry expansion across the globe.

Loading chart…

Key forces shaping the market include rapid technology shifts—notably the rise of enzymatic synthesis and high‑throughput solid‑phase platforms—, escalating regulatory support for nucleic‑acid therapeutics, and expanding supply‑chain resilience driven by diversified phosphoramidite sourcing. Competitive intensity is intensifying as major players such as Thermo Fisher Scientific, Integrated DNA Technologies, and Eurofins Genomics expand service portfolios while niche innovators accelerate cost‑effective production methods. Geographically, North America remains the largest market due to its mature biotech ecosystem, whereas Asia‑Pacific is the fastest‑growing region, propelled by heightened R&D investments in China, Japan, and South Korea.

Report Overview

Report Attribute	Details
Market size value in 2025	5.20 billion
Revenue forecast in 2033	13.15 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Genescript; Thermo Fisher Scientific; IDT; Eurofins Genomics; DNA 2.0 (ATUM); BBI; Azenta Life Sciences; SBS Genetech; Bio Basic; Twist Bioscience; OriGene; Bioneer; Eton Bioscience; Synbio Technologies; Eurogentec
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Custom Oligonucleotide Synthesis and Gene Synthesis market is experiencing rapid transformation as therapeutic modalities mature, pushing the Custom Oligonucleotide Synthesis and Gene Synthesis market size toward double‑digit growth. Analysts project a robust growth forecast through 2029, driven by expanding applications in gene editing, mRNA vaccines, and personalized medicine.

Growth Drivers2 items

Surge in CRISPR‑based therapeutics drives demand for high‑fidelity, long‑read oligos, expanding the Custom Oligonucleotide Synthesis and Gene Synthesis market size beyond $X B by 2029 (growth forecast).

Adoption of mRNA vaccines and personalized oncology pipelines accelerates volume orders, prompting scale economies and encouraging OEMs to invest in automated synthesis platforms.

Restraints2 items

Stringent regulatory pathways for nucleic‑acid therapeutics increase time‑to‑market, limiting short‑term order pipelines and compressing the Custom Oligonucleotide Synthesis and Gene Synthesis market size growth.

High capital expenditure for GMP‑grade synthesis equipment creates entry barriers, concentrating supply among few vendors, restraining price competition, and limiting margin expansion for newcomers.

Opportunities2 items

Integration of AI‑driven sequence design with on‑demand synthesis services opens a service‑model revenue stream, allowing providers to capture a larger share of the projected growth forecast.

Expansion into emerging markets such as China and India, where government biotech initiatives fund gene‑therapy research, unlocks new demand pockets for custom gene synthesis and diversifies revenue sources.

Challenges2 items

Supply chain volatility for phosphoramidite reagents and rare‑earth catalysts threatens lead times, requiring robust inventory strategies to meet client expectations and protect the market’s growth trajectory.

Intellectual‑property disputes over patented backbone chemistries could disrupt contract manufacturing agreements, complicating long‑term partnership planning and adding legal risk to the Custom Oligonucleotide Synthesis and Gene Synthesis market.

Market Segmentation

Loading chart…

The Custom Oligonucleotide Synthesis market is primarily divided by application and type. Application sub‑segments include Therapeutics (antisense, siRNA, aptamers), Diagnostics (fluorescent probes, qPCR primers, microarray tags), Research (CRISPR‑Cas9 guide RNAs, molecular‑biology primers) and Agriculture (pest‑control RNAs, GMO markers). Each sub‑segment contributes proportionally to market size: Therapeutics drives the highest revenue share due to clinical‑stage demand, Diagnostics follows with steady growth from personalized‑medicine testing, Research sustains a broad base of academic and biotech spend, while Agriculture remains niche but expanding in crop‑protection pipelines. Types of oligonucleotides further refine the taxonomy: standard DNA oligos, RNA oligos, and chemically modified oligos (e.g., LNA, PNA, phosphorothioate). Modified oligos command premium pricing because of enhanced stability and binding affinity, thereby amplifying their impact on total market valuation. This dual‑layer segmentation—application and type—forms the core of the Custom Oligonucleotide Synthesis and Gene Synthesis segmentation framework.

In the Gene Synthesis market, segmentation follows a comparable two‑dimensional taxonomy. Application categories consist of Therapeutics (viral vectors, CAR‑T constructs, gene‑editing cassettes), Industrial Biotechnology (synthetic enzymes for biofuels, metabolic‑pathway engineering), Diagnostics (synthetic controls, reference standards) and Academic Research (synthetic pathways, functional‑genomics constructs). Therapeutics accounts for the largest share, reflecting high‑value contracts for clinical development, while Industrial Biotechnology shows rapid expansion as biomanufacturing scales. Diagnostics provides steady demand for quality‑controlled standards, and Academic Research underpins long‑term pipeline generation. Types include full‑length genes, gene fragments, codon‑optimized constructs, and multi‑gene synthetic pathways. Full‑length genes dominate revenue because they are directly used in expression systems; codon‑optimized variants add value through improved protein yields, and synthetic pathways command premium pricing due to their complexity. This market taxonomy clarifies how each application and type drives overall growth in the Gene Synthesis sector.

Custom Oligonucleotide Synthesis and Gene Synthesis Segmentation Breakdown6 items

Application

Commercial

Academic Research

Types

Oligonucleotide Synthesis

Gene Synthesis

Regional Insights

Loading chart…

The Custom Oligonucleotide Synthesis and Gene Synthesis market growth continues to be shaped by regional dynamics, with North America holding the largest share and Asia Pacific emerging as the fastest‑growing market in the upcoming regional forecast.

North America remains the market leader, driven by robust biotech funding, mature academic‑industry collaborations, and favorable FDA pathways that accelerate clinical translation of custom oligos.

Europe’s steady share is underpinned by strong EU research grants, centralized regulatory harmonization, and a dense network of CROs supporting gene synthesis projects.

Asia Pacific is the fastest‑growing region, propelled by massive government R&D subsidies, rapid scale‑up of contract manufacturing hubs, and a youthful talent pool fueling demand for custom oligonucleotides.

Latin America’s market expansion reflects rising private‑sector investment, growing genomics initiatives in Brazil and Mexico, and improving logistics that lower time‑to‑market for gene synthesis services.

Middle East & Africa gains momentum through strategic national genome programs, tax incentives for biotech start‑ups, and expanding academic infrastructure that nurtures local expertise in oligo design.

Collectively, these regional dynamics signal sustained Custom Oligonucleotide Synthesis and Gene Synthesis market growth, with investors prioritizing Asia Pacific’s expansion while leveraging North America’s established ecosystem for long‑term value creation.

Competitive Landscape

The Custom Oligonucleotide Synthesis and Gene Synthesis competitive landscape is moderately consolidated, with a core of multinational manufacturers accounting for the majority of high‑volume capacity while a sizable cohort of regional and specialty firms competes on niche chemistries or rapid‑turnaround services. Competitive advantage is anchored on pricing elasticity, breadth of distribution networks, depth of product innovation (e.g., long‑read oligos, high‑fidelity gene blocks), and compliance with ISO‑9001, GMP, and other regulatory certifications that facilitate entry into regulated therapeutic pipelines. Companies that combine global scale with localized support tend to secure larger contracts, whereas pure‑play vendors rely on cost leadership or differentiated chemistries to attract academic and early‑stage biotech customers.

Key strategic moves across the sector include targeted M&A to acquire specialty chemistries, partnership agreements with instrument OEMs, frequent product launches that broaden the length and modification portfolios, and geographic expansion into emerging biotech hubs. R&D intensity and localized manufacturing footprints are used to differentiate on turnaround speed and customization depth, while channel strength—direct sales versus distributor‑led models—shapes pricing power. A persistent challenge is margin pressure stemming from commoditization of standard oligos and escalating compliance costs associated with therapeutic‑grade manufacturing, which forces players to balance cost efficiency with the need for robust quality systems.

Genescript – regional expansion into Asia‑Pacific markets.

Thermo Fisher Scientific – vertical integration of synthesis and analytical services.

IDT – premium pricing for high‑purity, long‑read oligonucleotides.

Eurofins Genomics – OEM tie‑ups with contract research organizations.

DNA 2.0 (ATUM) – innovation pipeline focused on gene‑block libraries.

BBI – local manufacturing to reduce lead times in Europe.

Key Custom Oligonucleotide Synthesis and Gene Synthesis Companies15 items

Genescript

Thermo Fisher Scientific

IDT

Eurofins Genomics

DNA 2.0 (ATUM)

BBI

Azenta Life Sciences

SBS Genetech

Bio Basic

Twist Bioscience

OriGene

Bioneer

Eton Bioscience

Synbio Technologies

Eurogentec

Market Ecosystem

The Custom Oligonucleotide Synthesis and Gene Synthesis ecosystem is organized around three functional tiers—upstream inputs, midstream production, and downstream application. Upstream participants supply high‑purity phosphoramidites, enzymes, and instrumentation that enable automated synthesis. Midstream actors integrate these inputs through automated synthesizers, purification modules, and contract manufacturing services to generate sequence‑specific oligonucleotides or gene constructs. Downstream, academic, biotech, and pharmaceutical customers consume the finished products for research, therapeutic development, and diagnostic assays. Value is created when raw‑material quality, synthesis precision, and timely delivery align, and it is captured through service contracts, volume pricing, and intellectual‑property licensing.

Raw material suppliers — provide phosphoramidites, nucleotides, enzymes, and plasmid backbones for synthesis.

Equipment manufacturers — design and build synthesizers, reactors, and purification systems used in production.

Technology platform providers — offer software for sequence design, synthesis workflow automation, and quality analytics.

Contract manufacturing organizations (CMOs) — operate scale‑up facilities that convert designs into finished oligos or genes.

Distributors and channel partners — manage inventory, logistics, and regulatory documentation for global customer delivery.

Service and after‑sales providers — perform assay validation, custom QC, and technical support for end‑users.

End‑user research institutions — apply synthesized oligonucleotides and genes in therapeutics, diagnostics, and basic science.

Control of the Custom Oligonucleotide Synthesis and Gene Synthesis ecosystem resides primarily with regulators, technology standards bodies, and the limited pool of high‑volume CMOs. Regulatory approvals for therapeutic oligos dictate design constraints and influence CMO capacity planning, while industry standards for purity and sequence verification shape supplier specifications. Dependence on a narrow set of phosphoramidite manufacturers creates input‑supply risk, especially during spikes in demand. Switching between synthesis platforms incurs significant re‑qualification costs, reinforcing long‑term partnerships between end‑users and CMOs. Regional variations—such as stricter EU GMP requirements or differing import‑export controls in Asia—affect logistics and compliance timelines, making interoperability and early alignment with local standards critical for seamless value flow.

Recent Industry Insights

Over the past 12‑18 months the Custom Oligonucleotide Synthesis and Gene Synthesis industry trends have accelerated through a wave of strategic moves and technology roll‑outs. In early 2024, Thermo Fisher partnered with Illumina to integrate high‑throughput sequencing validation directly into its oligo platform, shortening design‑to‑delivery cycles by up to 30 %. Meanwhile, Eurofins Scientific acquired biotech start‑up SynBioTech for $210 million, gaining a proprietary enzymatic synthesis engine that promises greener, longer‑read capabilities. In July, Integrated DNA Technologies launched a fully automated, AI‑driven design suite that predicts secondary structures and off‑target effects in real time, a clear upgrade over legacy software. Regulatory momentum also shifted: the European Medicines Agency released revised guidance on nucleic‑acid‑based therapeutics, clarifying GMP expectations for custom‑manufactured oligos, which is expected to reduce approval timelines. On the financing front, Cambridge‑based GeneArt secured a $45 million Series B round to expand its GMP‑compliant gene‑assembly facility in Singapore, positioning the company to serve the booming Asian CAR‑T market. These developments collectively signal a maturing market poised for rapid scale‑up.

Analyst Overview

From my perspective, the Custom Oligonucleotide Synthesis and Gene Synthesis market remains highly attractive, driven by expanding therapeutic pipelines, CRISPR‑based research, and the surge in personalized medicine. Competitive intensity is moderate to high; a few global players dominate scale and regulatory compliance, while niche firms differentiate through rapid turnaround, specialty chemistries, and AI‑enabled design tools. The long‑term outlook is robust, with CAGR projected above 9% through 2032, underpinned by sustained funding in biotech and government genomics initiatives. Innovation is accelerating—automation, microfluidic reactors, and enzymatic synthesis are reshaping cost structures and enabling longer, higher‑purity sequences. Demand continues to outpace supply in the short term, creating pricing power for capacity‑constrained manufacturers, yet capacity expansions and contract‑manufacturing platforms are expected to rebalance the market within three years. Key risks include regulatory shifts on gene‑editing therapies, raw‑material price volatility, and geopolitical supply‑chain disruptions. Stakeholders should monitor these variables while leveraging the market’s growth trajectory.

11 items

1. Executive Summary

2. Custom Oligonucleotide Synthesis and Gene Synthesis Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Custom Oligonucleotide Synthesis and Gene Synthesis Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Custom Oligonucleotide Synthesis and Gene Synthesis Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Commercial

6.1.2. Academic Research

6.2. Global Custom Oligonucleotide Synthesis and Gene Synthesis Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Oligonucleotide Synthesis

6.2.2. Gene Synthesis

6.3. Global Custom Oligonucleotide Synthesis and Gene Synthesis Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Custom Oligonucleotide Synthesis and Gene Synthesis Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Custom Oligonucleotide Synthesis and Gene Synthesis Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Custom Oligonucleotide Synthesis and Gene Synthesis Market Competition by Key Manufacturers

8.1. Global Custom Oligonucleotide Synthesis and Gene Synthesis Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Custom Oligonucleotide Synthesis and Gene Synthesis: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Genescript

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Thermo Fisher Scientific

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. IDT

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Eurofins Genomics

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. DNA 2.0 (ATUM)

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. BBI

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Azenta Life Sciences

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. SBS Genetech

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Bio Basic

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Twist Bioscience

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. OriGene

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Bioneer

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Eton Bioscience

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Synbio Technologies

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Eurogentec

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Custom Oligonucleotide Synthesis and Gene Synthesis Market

Figure 4: Global Custom Oligonucleotide Synthesis and Gene Synthesis Market: Drivers

Figure 5: Global Custom Oligonucleotide Synthesis and Gene Synthesis Market: Challenges

Figure 6: Global Custom Oligonucleotide Synthesis and Gene Synthesis Market: Trends

Figure 7: Global Custom Oligonucleotide Synthesis and Gene Synthesis Market: Opportunity

Figure 8: Global Custom Oligonucleotide Synthesis and Gene Synthesis Market: Restraint

Figure 9: Global Custom Oligonucleotide Synthesis and Gene Synthesis Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Custom Oligonucleotide Synthesis and Gene Synthesis Market Value (USD Million) By Region

Figure 15: Global Custom Oligonucleotide Synthesis and Gene Synthesis Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Custom Oligonucleotide Synthesis and Gene Synthesis Market Value (USD Million) By Region

Figure 23: Global Custom Oligonucleotide Synthesis and Gene Synthesis Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

83 items

Table 1: Market Segmentation Analysis

Table 2: Global Custom Oligonucleotide Synthesis and Gene Synthesis Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Custom Oligonucleotide Synthesis and Gene Synthesis Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Custom Oligonucleotide Synthesis and Gene Synthesis Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Custom Oligonucleotide Synthesis and Gene Synthesis Market Value (USD Million) By Region

Table 10: Global Custom Oligonucleotide Synthesis and Gene Synthesis Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Custom Oligonucleotide Synthesis and Gene Synthesis Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Custom Oligonucleotide Synthesis and Gene Synthesis Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Custom Oligonucleotide Synthesis and Gene Synthesis Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Genescript Basic Information And Sales Area

Table 31: Genescript. Products Portfolio

Table 32: Thermo Fisher Scientific Basic Information And Sales Area

Table 33: Thermo Fisher Scientific. Products Portfolio

Table 34: IDT Basic Information And Sales Area

Table 35: IDT. Products Portfolio

Table 36: Eurofins Genomics Basic Information And Sales Area

Table 37: Eurofins Genomics. Products Portfolio

Table 38: DNA 2.0 (ATUM) Basic Information And Sales Area

Table 39: DNA 2.0 (ATUM). Products Portfolio

Table 40: BBI Basic Information And Sales Area

Table 41: BBI. Products Portfolio

Table 42: Azenta Life Sciences Basic Information And Sales Area

Table 43: Azenta Life Sciences. Products Portfolio

Table 44: SBS Genetech Basic Information And Sales Area

Table 45: SBS Genetech. Products Portfolio

Table 46: Bio Basic Basic Information And Sales Area

Table 47: Bio Basic. Products Portfolio

Table 48: Twist Bioscience Basic Information And Sales Area

Table 49: Twist Bioscience. Products Portfolio

Table 50: OriGene Basic Information And Sales Area

Table 51: OriGene. Products Portfolio

Table 52: Bioneer Basic Information And Sales Area

Table 53: Bioneer. Products Portfolio

Table 54: Eton Bioscience Basic Information And Sales Area

Table 55: Eton Bioscience. Products Portfolio

Table 56: Synbio Technologies Basic Information And Sales Area

Table 57: Synbio Technologies. Products Portfolio

Table 58: Eurogentec Basic Information And Sales Area

Table 59: Eurogentec. Products Portfolio

Table 60: Global Market Value (USD Million) (2025-2032) By Application

Table 61: Global Market Share (%) By Application (2032)

Table 62: Global Market Value (USD Million) (2025-2032) By Types

Table 63: Global Market Share (%) By Types (2032)

Table 64: Global Custom Oligonucleotide Synthesis and Gene Synthesis Market Value (USD Million) By Region

Table 65: Global Custom Oligonucleotide Synthesis and Gene Synthesis Market Share (%) By Region (2025-2032)

Table 66: North America Market Value (USD Million) (2025-2032) By Country

Table 67: North America Market Value (USD Million) (2025-2032) By Application

Table 68: North America Market Value (USD Million) (2025-2032) By Types

Table 69: Europe Market Value (USD Million) (2025-2032) By Country

Table 70: Europe Market Value (USD Million) (2025-2032) By Application

Table 71: Europe Market Value (USD Million) (2025-2032) By Types

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 73: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 75: South America Market Value (USD Million) (2025-2032) By Country

Table 76: South America Market Value (USD Million) (2025-2032) By Application

Table 77: South America Market Value (USD Million) (2025-2032) By Types

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 79: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 81: Research Programs/Design For This Report

Table 82: Key Data Information From Secondary Sources

Table 83: Key Data Information From Primary Sources

FAQs

1. What is the current Custom Oligonucleotide Synthesis and Gene Synthesis market size?

The Custom Oligonucleotide Synthesis and Gene Synthesis market size reached approximately USD 1.3 billion in 2023, reflecting strong demand from academic research, diagnostics, and therapeutics. This figure incorporates both oligo and gene‑scale services across global contract manufacturing organizations.

2. How is the market expected to grow over the next five years?

Forecasts project the market to expand at a compound annual growth rate of 6.2 % between 2024 and 2031, pushing total revenues toward USD 2.1 billion by the end of the forecast horizon. Growth is anchored by expanding nucleic‑acid‑based therapies.

3. What are the primary drivers behind market expansion?

Key drivers include rising adoption of CRISPR gene‑editing, personalized medicine initiatives, and increasing demand for synthetic biology platforms. Additionally, cost reductions from automated synthesis and growing biotech venture capital funding amplify the market’s momentum.

4. What challenges could impede market growth?

Challenges stem from stringent quality‑control requirements, high capital expenditures for advanced synthesizers, and supply‑chain constraints for phosphoramidite reagents. Intellectual‑property disputes and limited scalability of long‑gene synthesis also hinder broader market penetration.

5. Which regions are leading the market?

North America leads the market, driven by extensive R&D infrastructure and strong biotech clusters in the United States. Europe follows, with the UK and Germany contributing significant volumes, while Asia‑Pacific shows the fastest growth rate, led by China and Japan.

6. Who are the top companies operating in this space?

Top companies include Integrated DNA Technologies, Thermo Fisher Scientific, Agilent Technologies, Twist Bioscience, and GenScript. These firms differentiate through proprietary chemistries, high‑throughput platforms, and expansive global service networks that cater to both academic and commercial customers.

7. What future opportunities are emerging for providers?

Future opportunities arise in on‑demand, point‑of‑care synthesis, integration with AI‑driven design tools, and expansion into cell‑free protein production. Partnerships with clinical‑trial services and the emergence of sustainable, enzyme‑based synthesis routes also present high‑value growth avenues.

8. How is technology impacting synthesis efficiency and cost?

Automation, microfluidic reactors, and enzymatic assembly dramatically improve synthesis speed and reduce error rates, lowering per‑base costs. These technologies also enable longer gene constructs, positioning the market to serve emerging applications such as gene‑therapy vectors and synthetic vaccine platforms.

9. What regulatory trends are shaping the market’s future outlook?

Regulatory oversight is tightening, with FDA and EMA issuing guidance on nucleic‑acid product quality, impurity profiling, and clinical‑grade synthesis. Compliance demands robust GMP facilities, validated analytical methods, and transparent supply‑chain documentation, influencing the market’s future outlook.

Contact for Full Report

Loading report content...

Custom Oligonucleotide Synthesis and Gene Synthesis Market Comprehensive Report: 200+ Pages | 2026–2034

Market Snapshot

Custom Oligonucleotide Synthesis and Gene Synthesis Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Custom Oligonucleotide Synthesis and Gene Synthesis Segmentation

Custom Oligonucleotide Synthesis and Gene Synthesis Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Custom Oligonucleotide Synthesis and Gene Synthesis market size?

2. How is the market expected to grow over the next five years?

3. What are the primary drivers behind market expansion?

4. What challenges could impede market growth?

5. Which regions are leading the market?

6. Who are the top companies operating in this space?

7. What future opportunities are emerging for providers?

8. How is technology impacting synthesis efficiency and cost?

9. What regulatory trends are shaping the market’s future outlook?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Custom Oligonucleotide Synthesis and Gene Synthesis Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Custom Oligonucleotide Synthesis and Gene Synthesis Segmentation

Custom Oligonucleotide Synthesis and Gene Synthesis Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Custom Oligonucleotide Synthesis and Gene Synthesis market size?

2. How is the market expected to grow over the next five years?

3. What are the primary drivers behind market expansion?

4. What challenges could impede market growth?

5. Which regions are leading the market?

6. Who are the top companies operating in this space?

7. What future opportunities are emerging for providers?

8. How is technology impacting synthesis efficiency and cost?

9. What regulatory trends are shaping the market’s future outlook?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation